| __timestamp | Bausch Health Companies Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 2983000000 |
| Thursday, January 1, 2015 | 2682700000 | 3426000000 |
| Friday, January 1, 2016 | 2810000000 | 3398000000 |
| Sunday, January 1, 2017 | 2582000000 | 3878000000 |
| Monday, January 1, 2018 | 2473000000 | 4056000000 |
| Tuesday, January 1, 2019 | 2554000000 | 4381000000 |
| Wednesday, January 1, 2020 | 2367000000 | 5151000000 |
| Friday, January 1, 2021 | 2624000000 | 5246000000 |
| Saturday, January 1, 2022 | 2625000000 | 5673000000 |
| Sunday, January 1, 2023 | 2917000000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Gilead Sciences, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in optimizing these costs.
From 2014 to 2023, Gilead Sciences consistently reported higher SG&A expenses, peaking at approximately $6.1 billion in 2023. This represents a 104% increase from their 2014 expenses. In contrast, Bausch Health's SG&A expenses grew by about 44% over the same period, reaching nearly $2.9 billion in 2023.
While Gilead's higher expenses might reflect aggressive marketing and expansion strategies, Bausch Health's more modest increase suggests a focus on cost efficiency. Understanding these trends provides valuable insights into each company's operational priorities and financial health.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Bausch Health Companies Inc.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Bausch Health Companies Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared